🇺🇸 FDA
Pipeline program

Intrarosa 6.5 mg pessary

Phase 3 small_molecule active

Quick answer

Intrarosa 6.5 mg pessary for Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome). is a Phase 3 program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).

Program details

Company
Istituto Gentili S.r.l.
Indication
Postmenopausal women with previous breast cancer or currently under anti-oesterogenic therapy (aromatase inhibitor +/- LHRH analogue) presenting vulvar, vaginal or urinary bothersome symptoms (genitourinary syndrome).
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials